Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index; 48 of the 126 sources its claims cite were checked for support.
Abstract
Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
Overview
CoChat Summary
TL;DR
An international ATTD consensus panel recommends standardized continuous glucose monitoring (CGM) time-in-range targets to complement A1C for type 1/type 2 diabetes, older/high-risk individuals, and pregnancy. It defines target TIR, TBR, and TAR cutpoints and cites evidence linking TIR to A1C and diabetes complications.
Key findings
- For type 1/type 2 diabetes, the panel recommends TIR 70–180 mg/dL >70% (>16 h 48 min), TBR <70 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), TAR >180 mg/dL <25% (<6 h), and TAR >250 mg/dL <5% (<1 h 12 min). For older/high-risk individuals, TIR target is >50% (>12 h), TBR <70 mg/dL <1% (<15 min), and TAR >250 mg/dL <10% (<2 h 24 min).
- For pregnancy in type 1 diabetes, the target range is 63–140 mg/dL (3.5–7.8 mmol/L), with TIR >70% (>16 h 48 min), TBR <63 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), and TAR >140 mg/dL <25% (<6 h); pregnancy type 2/GDM targets were not included because of limited evidence.
- TIR relates to A1C: TIR 70% and 50% corresponded with A1C approximately 7% (53 mmol/mol) and 8% (64 mmol/mol), respectively; every 10% increase in TIR corresponded to about 0.5% (5.5 mmol/mol) A1C reduction in Beck et al. (n=545 type 1 diabetes) and about 0.8% (8.7 mmol/mol) in Vigersky et al. (n=1,137 type 1/type 2).
- In DCCT data, hazard for retinopathy progression increased by 64% for each 10% reduction in TIR, and microalbuminuria development increased by 40%; in 3,262 people with type 2 diabetes, more advanced diabetic retinopathy was associated with less time in target range. The panel also recommends 14 days of CGM data, >70% CGM active, and %CV target <36% (some studies suggest <33%).
Methods
- Consensus process: in February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes expert in CGM; subgroups reviewed literature and presented evidence-based recommendations to the full panel for voting.
- Data/sample: no new primary trial was conducted; the paper synthesizes cited studies, including Beck et al. (n=545 type 1 diabetes), Vigersky et al. (n=1,137 type 1/type 2), Lu et al. (3,262 type 2 diabetes), DCCT analyses, and pregnancy CGM studies.
- Main analysis: narrative evidence synthesis and expert consensus on CGM metrics, time-in-range cutpoints, and standardized Ambulatory Glucose Profile reporting; no formal meta-analysis or systematic review is described.
Limitations
- The paper states that long-term trials demonstrating how CGM metrics relate to and/or predict clinical outcomes have not been conducted, and the evidence is suggestive; pregnancy percentages are based on limited evidence and more research is needed.
- The paper states there is no evidence regarding time in range for older and/or high-risk individuals, and CGM targets for women with GDM or type 2 diabetes in pregnancy were not included because of lack of evidence.
- Evident from the text: recommendations are consensus/expert opinion rather than a systematic review, and the consensus meeting/manuscript was funded by ATTD with support from multiple industry sponsors; many panel members report industry consulting, speaking, research, or advisory relationships.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 14 Not valid · 24 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
In type 1 diabetes, the Results (Table 2; page unavailable) show weaker correlations for hypoglycemia and glycemic variability than for mean glucose at 15 days. But they also show that both correlations increase as sampling extends from 3 to 15 days, contrary to the citing sentence’s claim that an increase with longer sampling has not been shown. The paper does not frame this analysis as >70% CGM use over 14 days. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] 41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther 2011;13:351-358. sourceExperimental — accuracy not yet measured
The Results (Table 2; page unavailable) show that correlations with the full three-month data increased as sampling lengthened for both hypoglycemia and glycemic variability. From 3 to 15 days, r² rose from 0.32 to 0.66 for values ≤70 mg/dL and from 0.36 to 0.70 for coefficient of variation—the opposite of the attributed claim. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The first longitudinal CGM data demonstrated a 13percentage point increase in TIR (43% to 56% TIR 70-140 mg/dL [3.9-7.8 mmol/L]) (61).”
What the sources say
- Disputedcites [61] 62. Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. N Engl J Med. 2016;375(7):644-654. sourceExperimental — accuracy not yet measured
The Study Outcomes report different CGM time-in-range results: 59.5% to 74.7% overnight and 56.8% to 66.3% over 24 hours with closed-loop therapy. The paper defines its target range as 63–140 mg/dL, not 70–140 mg/dL; it does not report the claimed increase from 43% to 56%. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Numerous studies have demonstrated significant clinical benefits of CGM use in people with diabetes regardless of insulin delivery method (1-15).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Partly supportedcites [2] 2. Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care 2017;40(4):538-545. sourceExperimental — accuracy not yet measured
The Introduction reports that several randomized trials found CGM benefits, including reduced HbA1c and hypoglycemia, particularly in adults with type 1 diabetes. But the Conclusions say this trial included only insulin-pump users; extending its results to people using injections is described as reasonable, not demonstrated. The paper therefore does not establish benefits regardless of insulin delivery method or across all people with diabetes. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Not checked — no full text of the sourcecites [5] 5. Polonsky WH, Hessler D, Ruedy KJ, Beck RW, for the DIAMOND Study Group. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care 2017; 40:736-741. source
- Supportedcites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. source
The Discussion reports significant glycemic benefits from real-time CGM that were comparable with pump (CSII) and injection (MDI) therapy. The study concerns people with type 1 diabetes. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [7] 7. van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, openlabel, crossover trial. Lancet Diabetes Endocrinol. 2016;4(11):893-902. source
- Not checked — no full text of the sourcecites [8] 8. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388:2254-2263. source
- Partly supportedcites [9] 9. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulintreated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73. sourceExperimental — accuracy not yet measured
The Results report significant reductions in hypoglycemic events with flash glucose monitoring in adults with insulin-treated type 2 diabetes, supporting a clinical benefit. The Results also state that 95% of participants used an insulin pen or syringe and 5% used continuous subcutaneous insulin infusion; the paper does not establish that the benefit held regardless of insulin delivery method. No page numbers are available in our copy. (LLM, conf=0.85)
- Partly supportedcites [10] 10. Choudhary P, Olsen BS, Conget I, et al. Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol Ther 2016;18(5):288-291. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says the CGM-based MiniMed 640G pump system can help patients with type 1 diabetes avoid hypoglycemia. But this short, uncontrolled study examined a predictive pump-suspension system, not CGM use regardless of insulin delivery method; it does not establish a benefit across delivery methods or isolate the benefit of CGM itself. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A1C is currently recognized as the key surrogate marker for the development of longterm diabetes complications in people with type 1 and type 2 diabetes and has been used the primary endpoint for many CGM studies (1; 3; 4; 6; 32; 33).”
What the sources say
- Not checked — no full text of the sourcecites [1] 1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA 2017;317(4):379-387 source
- Not checked — no full text of the sourcecites [3] 3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017; 317:371-378. source
- Not checked — no full text of the sourcecites [4] 4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365-374. source
- Could not verifycites [6] 6. ϲ͘ ŠŽƵƉĂů J͕ PĞƚƌƵǎĞůŬŽǀĄ L͕ FůĞŬĂē M͕ Ğƚ Ăů͘ CŽŵƉĂƌŝƐŽŶ ŽĨ ĚŝĨĨĞƌĞŶƚ ƚƌĞĂƚŵĞŶƚ ŵŽĚĂůŝƚŝĞƐ ĨŽƌ type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18(9):532-538. sourceExperimental — accuracy not yet measured
The Prespecified outcomes section (page unavailable) identifies HbA1c as this type 1 diabetes study’s primary endpoint. Neither that section nor the Discussion passages establish that A1C is the key surrogate marker for long-term complications in people with both type 1 and type 2 diabetes. Searches for that surrogate-marker relationship and for complications found no passage stating it. (LLM, conf=0.72)
- Partly supportedcites [33] 32. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55(12):3155-3162. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) links near-normal glycaemia with reduced complication risk in type 1 diabetes, and Methods > Outcome measure (page unavailable) uses HbA1c as this trial’s primary endpoint. The paper does not establish HbA1c as the key surrogate marker for long-term complications in both type 1 and type 2 diabetes. (LLM, conf=0.81)
- Could not verifycites [32] 31. Novodvorsky P, Bernjak A, Chow E, et al. Diurnal differences in risk of cardiac arrhythmias during spontaneous hypoglycemia in young people with type 1 diabetes. Diabetes Care 2017;40:655 ʹ 662. sourceExperimental — accuracy not yet measured
The Baseline Assessment section says HbA1c was measured at the start of monitoring, but does not describe it as a surrogate marker for long-term complications. The Research Design and Methods section examines arrhythmias during hypoglycemia, not A1C as a primary endpoint in CGM studies. Searches for the surrogate-marker and primary-endpoint claims found no supporting passage in our copy. (LLM, conf=0.76)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
37 more claims · 16 with their cited sources checked
Create a free account to see all 67 claims and to verify the 4 references still open.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the advent of newer studies of CGM in noninsulin‐treated individuals and increasing uptake, the utility of CGM is progressively being endorsed in this population.”
From Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycaemia is associated with an increased risk of vascular events, explaining recent consensus advocating hypoglycaemic exposure at <1% (i.e.<15 min/day) in individuals at high CV risk.137,138”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [138]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Considering the older age of participants and comorbid conditions reported, the mean HbA1c, GMI, TIR, and TBR results (8.0%, 7.6%, 56%, and 1.0% at 6 months, respectively) demonstrate close adherence to established glycemic targets (23, 24, 38).”
From Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Avaiable data suggest that such systems can increase TIR and reduce hypoglycemia in patients with DGP, with improvements comparable to those observed in individuals without gastrointestinal complications, although data remain limited and largely observational [153–157].”
From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A subsequent international consensus defined targets for most of the measures on the AGP that would correspond to individualized HbA 1c targets (193).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [193]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ FIGURES / TABLES · p. 4
“2 Figures / 3 Tables”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Time in Ranges · p. 11
“Table 4. Consensus guidance on cutpoints for assessment of glycemic control: Pregnancy”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citationIsmail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Self-citationBeck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 1×
“A1C is currently recognized as the key surrogate marker for the development of long-termdiabetes complications in people with type 1 and type 2 diabetes and has been used as the primary end point for many CGM studies (1,3,4,6,33,34).”
BackgroundSelf-citationBolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Cited by
Items 701–800 of 3,959
Malone, S. K., Peleckis, A. J., Grunin, L., Yu, G., Jang, S., Weimer, J. E., Lee, I., Rickels, M. R., & Goel, N. (2021) · Journal of Diabetes Research · doi:10.1155/2021/6611064 · Cited by 26
“These findings are clinically important because reducing glucose CV to <33% confers additional hypoglycemia protection compared to the recommended glucose CV of ≤36% [37, 40], which may be particularly critical for adults with 4 Journal of Diabetes Research”
BackgroundParise, M., Tartaglione, L., Cutruzzolà, A., Maiorino, M. I., Esposito, K., Pitocco, D., Gnasso, A., & Irace, C. (2021) · Journal of Medical Internet Research · doi:10.2196/24552 · Cited by 27
“…a pilot study to prospectively analyze the effectiveness of 2 structured virtual visits (video or telephone consultations) on the basis of the time in range (TIR), time above range (TAR), time below range (TBR), mean daily glucose, glucose management indicator (GMI), and glycemic variability [11].”
Sundberg, F., Nåtman, J., Franzén, S., Åkesson, K., & Särnblad, S. (2021) · Pediatric Diabetes · doi:10.1111/pedi.13211 · Cited by 28
Fantasia, K. L., Stockman, M.-C., Ju, Z., Ortega, P., Crable, E. L., Drainoni, M.-L., Walkey, A. J., Bergstrom, M., O'Brien, K., & Steenkamp, D. (2021) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2021.100254 · Cited by 25
“Of patients who received an eConsult, 23% (n = 3) had clinically significant hypoglycemia, defined as greater than 4% of sensor glucose readings < 70 mg/dL [22].”
BackgroundLiu, J. J., Spakowicz, D. J., Ash, G. I., Hoyd, R., Ahluwalia, R., Zhang, A., Lou, S., Lee, D., Zhang, J., Presley, C. J., et al. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009303 · Cited by 32
“We took glucose readings from the participant’s glucose sensor and aggregated them into 24-hour values by transforming the values into two clinically relevant indicators of glucose stability, percent-in-target and percent-above-target (25).”
MethodSelf-citationRosales, N., Battista, H. D., & Garelli, F. (2021) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2021.103106 · Cited by 30
Shah, V. N., Snell‐Bergeon, J. K., Demmitt, J. K., Joshee, P., Garcetti, R., Pyle, L. L., & Polsky, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0093 · Cited by 26
“17 However, our findings are similar to other studies reporting TIRs of 50%–68% in pregnant women with type 1 diabetes using CGM with or without insulin pump therapy, 7,8,19–21 suggesting that many women do not achieve the desired target proportion of glucose values within the goal TIR during…”
Wafa, I. A., Pratama, N. R., Sofia, N. F., Anastasia, E. S., Konstantin, T., Wijaya, M. A., Wiyono, M. R., Djuari, L., & Novida, H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0125 · Cited by 28
“0 mmol/L]), above range (>180mg/dL), and below range (<70mg/dL) [20].”
BackgroundDemographic and Glycemic Factors Linked With Diabetes Distress in Teens With Type 1 Diabetes
Inverso, H., LeStourgeon, L. M., Parmar, A., Bhangui, I., Hughes, B., Straton, E., Alford, M., Streisand, R. M., & Jaser, S. S. (2022) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsac049 · Cited by 27
Impact of Different Types of Data Loss on Optimal Continuous Glucose Monitoring Sampling Duration
Aktürk, H. K., Herrero, P., Oliver, N. S., Wise, H., Eikermann, E., Snell‐Bergeon, J. K., & Shah, V. N. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0093 · Cited by 25
“…et al. 16 For determining the optimal CGM duration to evaluate long-term glycemic con-trol, in line with the international consensus recommendation, 9 we selected percentage of time within target range 70–180 mg/dL (%T70–180), percentage of time below 70 mg/dL (%T < 70), percentage of time below…”
Rotondi, M. A., Wong, O. C. Y., Riddell, M. C., & Perkins, B. A. (2022) · Diabetes Care · doi:10.2337/dc21-2341 · Cited by 28
“8% reduction in HbA1c, depending on the baseline HbA1c levels and population characteristics (6).”
BackgroundGlocker, V., Bachmann, S., Hess, M., Szinnai, G., & Burckhardt, M.-A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.958671 · Cited by 25
Sugimoto, T., Tokuda, H., Miura, H., Kawashima, S., Ando, T., Kuroda, Y., Matsumoto, N., Fujita, K., Uchida, K., Kishino, Y., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14866 · Cited by 27
“0 mmol/L).(18,19) In 2019, an international consensus group recommended clinical targets for CGM data among individuals with diabetes.”
BackgroundInfluentialRingholm, L., Nørgaard, S. K., Rytter, A., Damm, P., & Mathiesen, E. R. (2022) · Nutrients · doi:10.3390/nu14224867 · Cited by 30
Glycaemic control in people with diabetes following acute myocardial infarction
Esdaile, H., Hill, N. E., Mayet, J., & Oliver, N. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110644 · Cited by 32
Klimontov, V. V., Mavlianova, K. R., Орлов, Н. Б., Semenova, J. F., & Korbut, A. I. (2023) · Biomedicines · doi:10.3390/biomedicines11102843 · Cited by 28
“The values of TIR > 70% were considered as targets [13] and values of CV 36% as indicators of stable glucose level [25].”
BackgroundMethodBAJAJ, H. S., Ásbjörnsdóttir, B., Carstensen, L., Laugesen, C., Mathieu, C., Philis‐Tsimikas, A., & Battelino, T. (2024) · Diabetes Care · doi:10.2337/dc23-2136 · Cited by 28
Self-citationCritical Reappraisal of the Time-in-Range: Alternative or Useful Addition to Glycated Hemoglobin?
Heinemann, L., Freckmann, G., Müller‐Wieland, D., & Kellerer, M. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819883885 · Cited by 28
“Hence, the measurement error is approximately 4% as compared to 5% for HbA1c.”
MethodInfluentialSelf-citationGomez-Peralta, F., Abreu, C., Gomez-Rodriguez, S., Cruz-Bravo, M., María-Sanchez, C., Poza, G., & Ruiz-Valdepeñas, L. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0427 · Cited by 25
“Glycemic variability indices were monitored according to international recommendations 13,14 with the FreeStyle Libre Pro and included glucose standard deviation (SD), time in range (TIR), time above range (TAR), and time below range (TBR).”
Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care
Unger, J., Kushner, P. R., & Anderson, J. E. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1744393 · Cited by 28
A case study on using a large language model to analyze continuous glucose monitoring data
Healey, E., Tan, A. L. M., Flint, K. L., Ruiz, J., & Kohane, I. S. (2025) · Scientific Reports · doi:10.1038/s41598-024-84003-0 · Cited by 36
“These tasks were created using a guide for interpretation of AGPs 20 that was largely based on an international consensus report 21 and in line with recommendations from the American Diabetes Association (ADA) “Standards of Care in Diabetes” 22 .”
Zhou, Y., Sardana, D., Kuroko, S., Haszard, J. J., de Block, M. I., Weng, J., Jefferies, C., & Wheeler, B. J. (2024) · Diabetic Medicine · doi:10.1111/dme.15280 · Cited by 25
“21 12 Of note, no significant differences in HbA1c were seen, although certainty of this evidence was low.”
BackgroundKumar, S., Soldatos, G., Ranasinha, S., Teede, H., & Pallin, M. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.07.013 · Cited by 24
Rancati, S., Bosoni, P., Schiaffini, R., Deodati, A., Mongini, P. A., Sacchi, L., Toffanin, C., & Bellazzi, R. (2024) · Diabetology · doi:10.3390/diabetology5060042 · Cited by 31
“Time Severely Below Range (TBR For ease of interpretation, the same colors as those used in the Advanced Technologies & Treatments for Diabetes (ATTD) consensus report [38] are applied in the fi gure.”
Jacobsen, L. M., & Schatz, D. (2026) · JAMA · doi:10.1001/jama.2026.0048 · Cited by 34
Self-citationLepore, G., Scaranna, C., Corsi, A., Dodesini, A. R., & Trevisan, R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0302 · Cited by 24
Tumminia, A., Milluzzo, A., Festa, C., Fresa, R., Pintaudi, B., Scavini, M., Vitacolonna, E., Napoli, A., & Sciacca, L. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.03.013 · Cited by 29
Achieving the HbA1c Target Requires Longer Time in Range in Pregnant Women With Type 1 Diabetes
Ling, P., Yang, D., Gu, N., Xiao, X., Lü, J., Liu, F., Zhou, Z., Huang, Q., Zhao, J., Zhang, M., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab502 · Cited by 27
“0 mmol/L (TAR), mean blood glucose, SD, coefficient of variation, and mean amplitude of glycemic excursions, high blood glucose indices, low blood glucose indices, and area under the curve (7).”
BackgroundInfluentialSibiak, R., Gutaj, P., Mrzewka-Rogacz, B., Mantaj, U., & Wender-Ożegowska, E. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0194 · Cited by 25
“28 International consensus on CGM use defined several other CGM metrics implemented in our study—that is, mean glucose, %CV, LBGI, and HBGI.”
Yoo, J. H., Kim, J. Y., & Kim, J. H. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0165 · Cited by 27
Noninvasive Glucose Sensing In Vivo
Leung, H. M. C., Forlenza, G. P., Prioleau, T., & Zhou, X. (2023) · Sensors · doi:10.3390/s23167057 · Cited by 36
“People with T1D should aim to reach TIR > 70%, which is shown to reduce the risk of long-term complications [30].”
BackgroundNørgaard, K., Ranjan, A. G., Laugesen, C., Tidemand, K. G., Green, A., Selmer, C., Svensson, J., Andersen, H. U., Vistisen, D., & Carstensen, B. (2023) · Diabetes Care · doi:10.2337/dc23-1137 · Cited by 31
Self-citationPérez-López, P., Fernández-Velasco, P., Bahillo-Curieses, P., de Luis, D. A., & Díaz-Soto, G. (2023) · Endocrine · doi:10.1007/s12020-023-03511-7 · Cited by 30
“The CGM offers an interesting alternative, allowing a comprehensive assessment of interstitial blood glucose levels on a continuous basis, with the time in range (TIR) of 70 – 180 mg/dl, the measure with the most support at present [5].”
BackgroundSobhani, N. C., Goemans, S. L., Nguyen, A. T., Chambers, M. E., Richley, M., Gabby, L. C., Field, N. T., Han, C. S., & Ramos, G. A. (2024) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2024.01.010 · Cited by 31
A clinical review of the t:slim X2 insulin pump
Berget, C., Lange, S. L., Messer, L. H., & Forlenza, G. P. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1814734 · Cited by 27
Utilizing continuous glucose monitoring in primary care practice: What the numbers mean
Edelman, S. V., Cavaiola, T. S., BOEDER, S. C., & Pettus, J. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.10.013 · Cited by 27
Kruger, D. F., & Anderson, J. E. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0193 · Cited by 30
“86,138 These metrics have been adopted by several national and international medical organizations.”
Battelino, T., Bosnyak, Z., Danne, T., Mukherjee, B., Edelman, S., Pilorget, V., Choudhary, P., Renard, E., & Bergenstal, R. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00781-6 · Cited by 23
Self-citationAbraham, M. B., Smith, G. J., Dart, J., Clarke, A. D., Bebbington, K. R., Fairchild, J. M., Ambler, G. R., Cameron, F. J., Davis, E. A., & Jones, T. W. (2024) · Diabetes Care · doi:10.2337/dc24-0276 · Cited by 30
Avari, P., Choudhary, P., Lumb, A. N., Misra, S., Rayman, G. A., Flanagan, D., Dhatariya, K., & the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP) group (2024) · Diabetic Medicine · doi:10.1111/dme.15452 · Cited by 34
Lu, Y., Liu, D., Liang, Z., Liu, R., Chen, P., Liu, Y., Li, J., Feng, Z., Li, L. M., Sheng, B., et al. (2025) · National Science Review · doi:10.1093/nsr/nwaf039 · Cited by 45
“We selected three representative metrics in each group: standard deviation (SD), estimated A1C (eA1C) [36 ], and time in range (TIR) [37 ] showing their moderate consistenc y w ith CGMformer’s embedded vectors (Fig.”
Self-citationHutchins, K., Betts, J. A., Thompson, D., Hengist, A., & Gonzalez, J. T. (2025) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.02.024 · Cited by 33
“To examine the potential impact on interpretations of time-in-range (or time-out-of-range), the time spent above the American Diabetes Association secondary target range (7.8 mmol/L [16]) was calculated for each participant and summed across all 7 laboratory visits.”
InfluentialJuel, C. T., Dejgaard, T. F., Hansen, C. P., Storkholm, J. H., Vilsbøll, T., Lund, A., & Knop, F. K. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa731 · Cited by 26
Ahmad, N. N., Ghazali, N. N. N., & Wong, Y. H. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113384 · Cited by 24
Chung, S. M., Lee, Y. H., Kim, C. O., Lee, J. Y., Jin, S., Yoo, S.-H., Moon, J. S., & Kim, K. J. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e190 · Cited by 24
Frank, J., Blissett, D. B., Hellmund, R., & Virdi, N. S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0263 · Cited by 30
Low-Carbohydrate Diet among Children with Type 1 Diabetes: A Multi-Center Study
Neuman, V., Plachý, L., Průhová, Š., Koloušková, S., Petruželková, L., Obermannová, B., Vyzralkova, J., Konečná, P., Vosáhlo, J., Romanová, M., et al. (2021) · Nutrients · doi:10.3390/nu13113903 · Cited by 26
“CGM data taken from the last 14 days before the last visit before the survey distribution were downloaded using a specialized software (Diasend, LibreView, CareLink) and the values for standard CGM metrics [30] were used for the analysis—time in the target range (TIR) (between 3.”
MethodBellido, V., & Pérez, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10225341 · Cited by 31
“The values for elderly or frail patients are reaching time in range >50% and time in hypoglycemia <1% [47,48].”
BackgroundTime-in-range and frequency of continuous glucose monitoring: Recommendations for South Asia
Kesavadev, J., Misra, A., Saboo, B., Agarwal, S., Sosale, A., Joshi, S., Hussain, A., Somasundaram, N. P., Basit, A., Choudhary, P., et al. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102345 · Cited by 24
Self-citationSymbolic Control Design of an Artificial Pancreas for Type-2 Diabetes
Borri, A., Pola, G., Pepe, P., Benedetto, M. D. D., & Palumbo, P. J. (2021) · IEEE Transactions on Control Systems Technology · doi:10.1109/tcst.2021.3135320 · Cited by 27
“good glucose control published in the International Consensus reports [67], [68] to further evaluate the control performance.”
BackgroundSerné, E. H., Roze, S., Buompensiere, M. I., Valentine, W. J., de Portu, S., & de Valk, H. W. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02058-9 · Cited by 27
“An additional direct comparison of the technologies showed that patients using RT-CGM experienced a shorter time in hypoglycemia and more time in range than patients using IS-CGM [20].”
ResultNimri, R., Tirosh, A., Muller, I., SHTRIT, Y., Kraljević, I., Alonso, M. M., Milicic, T. J., Saboo, B., Deeb, A., Christoforidis, A., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0566 · Cited by 28
Self-citationBombaci, B., Passanisi, S., Alibrandi, A., D’Arrigo, G., Patroniti, S., Averna, S., Salzano, G., & Lombardo, F. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191610293 · Cited by 30
“Recommendations on clinical targets for continuous glucose monitoring data interpretation suggest that CV is the most suitable glucose metric to identify short-term glycemic variability and levels should be maintained below 36% [31].”
BackgroundViroonluecha, P., Egea-López, E., & Santa, J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274608 · Cited by 31
“T1D patients should aim for a target range of 70–180 mg/dL [47].”
BackgroundPasqua, M., Jafar, A., Kobayati, A., Tsoukas, M. A., & Haidar, A. (2022) · Diabetes Care · doi:10.2337/dc22-0490 · Cited by 30
McCarthy, O. M., Christensen, M. B., Kristensen, K. B., Schmidt, S., Ranjan, A. G., Bain, S. C., Bracken, R. M., & Nørgaard, K. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0009 · Cited by 26
Self-citationDiabetic neuropathy: Past, present, and future.
Aldave, J. E. Q., Durand‐Vásquez, M. D. C., Osorio, E. R. G., Suárez-Rojas, J., Roseboom, P. J., Alcalá‐Mendoza, R. M., Arroyo, J., Zavaleta‐Gutiérrez, F. E., Urteaga, L. A. C., & Concepción‐Zavaleta, M. J. (2023) · PubMed Central · doi:10.22088/cjim.14.2.153 · Cited by 49
Gao, F., Ma, X., Peng, J., Lu, J., Lu, W., Zhu, W., Bao, Y., Vigersky, R. A., Jia, W., & Zhou, J. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0290 · Cited by 24
Self-citationEhrmann, D., Priesterroth, L., SCHMITT, A. J., Kulzer, B., & Hermanns, N. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0096 · Cited by 24
Benhalima, K., Durnwald, C. P., Sweeting, A., Adams, D., Addala, A., Battelino, T., Bergenstal, R. M., Carlson, A. L., Donovan, L., Franco, D. R., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00335-3 · Cited by 38
Self-citationCrossen, S. S., Romero, C. C., Lewis, C., & Glaser, N. S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1063290 · Cited by 22
Drenthen, L. C. A., de Baaij, J. H. F., Rodwell, L., van Herwaarden, A. E., Tack, C. J., & de Galan, B. E. (2023) · Diabetologia · doi:10.1007/s00125-023-06029-9 · Cited by 37
“A hypoglycaemic event was defined as a glucose concentration 3.9 mmol/l for at least 15 consecutive minutes and a new event was calculated if the glucose concentration had been above this level for at least 15 min [24].”
MethodInfluentialBattarbee, A. N., Sauer, S. M., Sanusi, A. A., & Fulcher, I. (2024) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2024.03.026 · Cited by 26
Future horizons in diabetes: integrating AI and personalized care
Zhang, K., Qi, Y. P., Wang, W., Tian, X., Wang, J., Xu, L., & Zhai, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1583227 · Cited by 36
Battelino, T., Kuusela, S., Shetty, A., Rabbone, I., Cherubini, V., Campbell, F., Ahomäki, R., Tuomaala, A., Peters, C. J., Iafusco, D., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00091-9 · Cited by 28
Self-citationRelationship between daily and visit-to-visit glycemic variability in patients with type 2 diabetes
Tsuchiya, T., Saisho, Y., Murakami, R., Watanabe, Y., Inaishi, J., & Itoh, H. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0012 · Cited by 23
“In addition, time-in-range (TIR; percentage of time that the CGM readings were within the target range of 70–180 mg/dL), time-above-range (TAR; >180 mg/dL) and time-below-range (TBR; <70 mg/dL) were also assessed from the CGM data.”
BackgroundMethodInfluentialKim, J. H. (2020) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2040038.019 · Cited by 22
Suzuki, J., Urakami, T., Yoshida, K., Kuwabara, R., Mine, Y., Aoki, M., & Morioka, I. (2020) · Pediatrics International · doi:10.1111/ped.14412 · Cited by 26
Self-citationThe influence of time in range on daily mood in adults with type 1 diabetes
Polonsky, W. H., & Fortmann, A. L. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107746 · Cited by 29
Lemieux, P., Yamamoto, J. M., & Donovan, L. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.01.006 · Cited by 24
Gáborová, M., Doničová, V., Bačová, I., Pallayová, M., Bona, M., Peregrim, I., Gresova, S., Stimmelova, J., Dzugasová, B., Blichová, L. Š., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18073402 · Cited by 22
“The recent recommendations from the international consensus on time in range decided that the important metrics for CGM are the percentage of time spent-in –range (%TIR), time-above-target range (%TAR) and time-below-target range (%TBR) [14].”
BackgroundTattoo Inks for Optical Biosensing in Interstitial Fluid
Pazos, M. D., Hu, Y., Elani, Y., Browning, K. L., Jiang, N., & Yetisen, A. K. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101238 · Cited by 28
Seget, S., Rusak, E., Polańska, J., & Jarosz-Chobot, P. A. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0148 · Cited by 23
“of HbA1c was used.(5) It was a prospective, open-label, singlearm, single-center study, and it was carried out at the largest Polish center of pediatric diabetology, a member of SWEET.”
BackgroundPiccini, B., Pessina, B., Casalini, E., Lenzi, L., & Toni, S. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13440 · Cited by 24
MacLeod, J., & Vigersky, R. A. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221134546 · Cited by 34
AGATA: A Toolbox for Automated Glucose Data Analysis
Cappon, G., Sparacino, G., & Facchinetti, A. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221147570 · Cited by 23
“The toolbox provides six functions to calculate glucose control metrics related to the percentage of time spent in a specific glycemic zone, that is, hypoglycemia, hyperglycemia (%T HYPER ), target range (%T TARGET ), severe hypoglycemia, severe hyperglycemia, and tight target range, as defined in the study by Batteli…”
InfluentialToschi, E. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.10.006 · Cited by 25
van den Boom, L., Auzanneau, M., Woelfle, J., Sindichakis, M., Herbst, A., Meraner, D., Hake, K., Klinkert, C., Gohlke, B. C., & Holl, R. W. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231156601 · Cited by 26
“25 With increasing use of CGM technology during recent years, limitations of HbA1c, which has been the gold standard for assessing glycemic control, have received more attention.”
de Oliveira, B. F., Chang, C. R., Oetsch, K. M., Falkenhain, K., Crampton, K., Stork, M., Hoonjan, M., Elliott, T. G., François, M. E., & Little, J. P. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.04.032 · Cited by 30
Lepore, G., Borella, N. D., Castagna, G., Ippolito, S., Bonfadini, S., Corsi, A., Scaranna, C., Dodesini, A. R., Bellante, R., & Trevisan, R. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0261 · Cited by 23
Hettiarachchi, C., Malagutti, N., Nolan, C. J., Suominen, H., & Daskalaki, E. (2022) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2023.105839 · Cited by 36
Eviz, E., Kıllı, N. E., Karakus, K. E., Can, E., Gökçe, T., Mutlu, G. Y., & Hatun, Ş. (2024) · Diabetic Medicine · doi:10.1111/dme.15333 · Cited by 24
Pinsker, J. E., Leas, S., Müller, L., & Habif, S. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0554 · Cited by 22
Nagl, K., Berger, G., Aberer, F., Ziko, H., Weimann, K., Bozic, I., Rami-Merhar, B. M., & Mader, J. K. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13160 · Cited by 24
Valli, G., Minnock, D., Tarantino, G., & Neville, R. D. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.12.006 · Cited by 23
Perea, V., César, M. J. P., Megía, A., Goya, M., Wägner, A. M., Guedes, B. V., Seguí, N., Montañez, M. D., & Vinagre, I. (2022) · Diabetologia · doi:10.1007/s00125-022-05717-2 · Cited by 24
Klonoff, D. C., Bergenstal, R. M., Cengiz, E., Clements, M. A., Espes, D., Espinoza, J., Kerr, D. E., Kovatchev, B. P., Maahs, D. M., Mader, J. K., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251353228 · Cited by 37
“49 Healey and colleagues evaluated the ability of an LLM, GPT-4, to compute quantitative metrics specific to diabetes found in an AGP as defined by an international consensus report 50 and an American Diabetes Association Standards of Care in Diabetes report.”
Self-citationIdrees, T., Castro-Revoredo, I. A., Oh, H. D., Gavaller, M. D., Zabala, Z., Moreno, E., Moazzami, B., Galindo, R. J., Vellanki, P., Cabb, E., et al. (2024) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2024.01.031 · Cited by 22
Continuous Glucose Monitoring in Older Adults: What We Know and What We Have Yet to Learn
Price, C. E., Callahan, K. E., Aloi, J., & Usoh, C. O. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241234651 · Cited by 25
Desouter, A. K., Keymeulen, B., de Velde, U. V., Dalem, A. V., Lapauw, B., Block, C. E. M. D., Gillard, P., Seret, N., Balti, E. V., Vooren, E. R. V., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2376 · Cited by 28
Halperin, I. J., Wicklow, B., Amed, S., Chambers, A., Courage, C., Cummings, E., Kirkland, P., MacKay, D., Nakhla, M., Punthakee, Z., et al. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.01.001 · Cited by 22
Conti, M., Massari, G., Meneghini, E., Pasquino, B., Agosti, B., Chinotti, F., Pintaudi, B., Girelli, A., & Bertuzzi, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030642 · Cited by 21
“The study endpoints were to evaluate changes in HbA1c levels and changes in CGM metrics as defined by the International Consensus on Time in Range [18] from baseline to a 3-and a 6-month follow-up.”
MethodBeyond A1C: exploring continuous glucose monitoring metrics in managing diabetes
Friedman, J. G., Coyne, K., Aleppo, G., & Szmuilowicz, E. D. (2023) · Endocrine Connections · doi:10.1530/ec-23-0085 · Cited by 22
Hypoglycaemia and its management in primary care setting
Ibrahim, M., Baker, J., Cahn, A., Eckel, R. H., El Sayed, N. A., Fischl, A. H., Gaede, P., Leslie, R. D., Pieralice, S., Tuccinardi, D., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3332 · Cited by 21
“9 mmol/L) recommendation is different for the general population of patients with diabetes and for type 1 patients during pregnancy (below 4%) vs older/high risk patients (below 1%).(91)”
BackgroundSherwood, J. S., Castellanos, L. E., O’Connor, M. Y., BALLIRO, C. A., HILLARD, M. A., Gaston, S. G., Bartholomew, R. A., Greaux, E. G., Sabean, A., Zheng, H., et al. (2023) · Diabetes Care · doi:10.2337/dc23-1411 · Cited by 24
How to Measure Glycemic Variability? A Literature Review
Lazăr, S., Ioniță, I., Reurean‐Pintilei, D., & Timar, B. (2023) · Medicina · doi:10.3390/medicina60010061 · Cited by 29
“TIR is becoming an emerging standard in the evaluation of DM management [16].”
BackgroundDiagnosis and Treatment of Hyperglycemia in Pregnancy
Mohan, S., & Egan, A. M. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.05.011 · Cited by 41
Current landscape and comprehensive management of glycemic variability in diabetic retinopathy
Chen, B., Shen, C., & Sun, B. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05516-w · Cited by 24
“…Advanced Technologies & Treatments for Diabetes International Consensus recommended a CV threshold of 36% in clinical practice [48], and studies found that individuals with a CV > 36% experienced three-to six-fold higher risk of hypoglycemic events compared with those with a CV of ≤ 36% [22, 48].”
BackgroundBurk, J., Ross, G. P., Hernandez, T. L., Colagiuri, S., & Sweeting, A. (2025) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.04.010 · Cited by 26
Gaudillère, M., Pollin-Javon, C., Brunot, S., Fimbel, S., & Thivolet, C. H. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101251 · Cited by 23
Metadata
- Authors
- Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., Cobelli, C., Dassau, E., DeVries, J. H., Donaghue, K. C., Dovc, K., Doyle, F. J., Garg, S., Grunberger, G., Heller, S., Heinemann, L., Hirsch, I. B., Hovorka, R., Jia, W., Kordonouri, O., Kovatchev, B., Kowalski, A., Laffel, L., Levine, B., Mayorov, A., Mathieu, C., Murphy, H. R., Nimri, R., Nørgaard, K., Parkin, C. G., Renard, E., Rodbard, D., Saboo, B., Schatz, D., Stoner, K., Urakami, T., Weinzimer, S. A., & Phillip, M.
- Affiliations
- University of Ljubljana (SI)
- Kinderkrankenhaus auf der Bult (DE)
- Park Nicollet Health Services (US)
- King's College London (GB)
- Jaeb Center for Health Research (US)
- Vita-Salute San Raffaele University (IT)
- Stanford Medicine (US)
- American Diabetes Association (US)
- Close Concerns (United States) (US)
- University of Padua (IT)
- Harvard University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- The University of Sydney (AU)
- Department of Pediatric Endocrinology, Diabetes and Metabolism, University Children’s Hospital, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Slovenia
- University of Colorado Denver (US)
- Grunberger Diabetes Institute (US)
- University of Sheffield (GB)
- Science Consulting in Diabetes, Neuss, Germany
- University of Washington (US)
- University of Cambridge (GB)
- Shanghai Jiao Tong University (CN)
- University of Virginia (US)
- Breakthrough T1D (US)
- Joslin Diabetes Center (US)
- Endocrinology Research Center (RU)
- KU Leuven (BE)
- University of East Anglia (GB)
- Schneider Children's Medical Center (IL)
- Steno Diabetes Center Copenhagen (DK)
- CGParkin Communications, Inc., Henderson, NV
- Department of Endocrinology, Diabetes, and Nutrition, Montpellier University Hospital; Institute of Functional Genomics, University of Montpellier; and INSERM Clinical Investigation Centre, Montpellier, France
- Biomedical Informatics Consultants LLC, Potomac, MD
- DiaCare, Ahmedabad, Gujarat, India
- University of Florida (US)
- dQ&A Market Research, Inc., San Francisco, CA
- Nihon University (JP)
- Yale University (US)
- Tel Aviv University (IL)
- Corresponding author
- Battelino, Tadej
- ORCID
- Battelino, Tadej
- Danne, Thomas
- Bergenstal, Richard M.
- Amiel, Stephanie A.
- Beck, Roy
- Biester, Torben
- Bosi, Emanuele
- Buckingham, Bruce A.
- Cefalu, William T.
- Close, Kelly L.
- Cobelli, Claudio
- Dassau, Eyal
- DeVries, J. Hans
- Donaghue, Kim C.
- Doyle, Francis J.
- Garg, Satish
- Grunberger, George
- Heller, Simon
- Heinemann, Lutz
- Hirsch, Irl B.
- Hovorka, Roman
- Jia, Weiping
- Kordonouri, Olga
- Kovatchev, Boris
- Kowalski, Aaron
- Laffel, Lori
- Levine, Brian
- Mayorov, Alexander
- Mathieu, Chantal
- Murphy, Helen R.
- Nimri, Revital
- Nørgaard, Kirsten
- Parkin, Christopher G.
- Renard, Eric
- Rodbard, David
- Saboo, Banshi
- Schatz, Desmond
- Stoner, Keaton
- Urakami, Tatsuiko
- Weinzimer, Stuart A.
- Phillip, Moshe
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-08
- Volume
- 42
- Issue
- 8
- Pages
- 1593-1603
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6973648
- OpenAlex
- W2948261890
- Cited by
- 4,237
- References
- 96
- Citations by year
- 2026: 716 · 2025: 649 · 2024: 655 · 2023: 575 · 2022: 619 · 2021: 556 · 2020: 398 · 2019: 61
- FWCI
- 215.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Lirias (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Leona M. and Harry B. Helmsley Charitable Trust
- University of Virginia
- Insulet Corporation
- MannKind Corporation
- Dexcom
- OPKO Health
- Steno Diabetes Center Copenhagen (SDCC 3.E Technology)
- National Institute for Health and Care Research (NF-SI-0515-10079, CDF-2013-06-035, 16/35/01)
- Universiteit van Amsterdam
- KU Leuven
- Novo Nordisk
- Roche Diabetes Care
- National Institutes of Health (UL1TR001863)
- U.S. Food and Drug Administration
- Abbott Diabetes Care
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- continuous glucose monitoring, time in range, glycemic targets, diabetes management, clinical guidelines
- MeSH terms
- Data Accuracy, Blood Glucose, Data Interpretation, Statistical, Diabetes Mellitus, Glycated Hemoglobin, Humans, Patient Care Planning, Reference Values, Time Factors, Blood Glucose Self-Monitoring, Practice Guidelines as Topic, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.